Older regional comparative studies report anxiolytic signals in generalized anxiety and related disorders, but modern large placebo-controlled independent replication is sparse.
Regulatory status
Not FDA/EMA-approved; FDA highlights limited safety information for compounded use.
Main limitations
Modern first-line anxiolytic efficacy, healthy-person cognitive enhancement, long-term safety or a validated compounded regimen.
Safety
International safety dataset is limited; FDA notes insufficient safety information for compounded Selank.
i
Older regional comparative studies report anxiolytic signals in generalized anxiety and related disorders, but modern large placebo-controlled independent replication is sparse.
What the evidence actually supports
✓Potentially useful research summary; avoid 'better/safer than benzodiazepines' claims.
✓Useful human evidence, but not enough to treat Selank as a mainstream established anxiolytic.
✓Present as limited human evidence, not established first-line anxiolytic therapy.
✓Keep efficacy signals and contemporary compounded-product safety uncertainty separate.
What is not established / key limitations
×Evidence base is small, older, regionally concentrated, and not a modern large multicentre programme.
×No modern large multicentre replication identified.
×No large modern placebo-controlled multicenter efficacy programme was identified.
×No validated long-term safety framework is established.
Selected study & evidence records
Selank versus medazepam in generalized anxiety disorder and neurasthenia
2008 · Randomized comparative clinical study · n=62
Selank and medazepam produced similar anxiolytic effects; authors also reported antiasthenic/psychostimulant effects with Selank.
International safety dataset is limited; FDA notes insufficient safety information for compounded Selank.
FDA says important safety information for compounded Selank acetate is lacking; aggregation, impurities and immunogenicity are relevant formulation concerns.
Technical details
Mechanism / biologyProposed modulation of GABAergic and neuroimmune signalling; exact clinical mechanism remains uncertain.
Route / formulation boundaryRegional intranasal studies do not establish universal product equivalence or long-term safety.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Dosing evidence statusVerified human study regimen added with conference-abstract caveat. A 20-patient GAD study reported Selank 2700 micrograms/day intranasally. This is a study exposure from a conference abstract, not an approved or validated general-use regimen.
Identifiers & alternate namesnasal SELANK
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
